The Use of Efavirenz As a Part of Late Rescue Antiretroviral Treatment

REFERENCES

• Hirschel B, Opravil M. The year in review: Antiretroviral treatment. AIDS. 1999;13(suppl. A):S177–S187.
   PubMed Web of Science ®Google Scholar
• Carpenter CCJ, Fischl MA, Hammer SM, et al. Antiretroviral therapy for HIV infection in 1998: Updated recommenda-tions of the International AIDS Society-USA panel. JAMA. 1998; 280:78–86.
   PubMed Web of Science ®Google Scholar
• Carpenter CCJ, Cooper DA, Fischl MA, et al. Antiretroviral therapy in adults: Updated recommendations of the Interna-tional AIDS Society-USA Panel. JAMA. 2000;283:381–390.
   PubMed Web of Science ®Google Scholar
• Gallant JE. Strategies for long-term success in the treat-ment of HIV infection. JAMA. 2000; 283:1329–1334.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Chiodo F. Substitution of protease inhibitors during treatment of patients with human immunodeficiency virus infection: Frequency, mode, reasons, and mid-term outcome. J Antimicrob Chemother. 2000;45:261–263.
   PubMed Web of Science ®Google Scholar
• Hirsch MS, Conway B, D'Aquila RT, et al. Antiretroviral drug resistance testing in adults with HIV infection. JAMA. 1998;279:1984–1991.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Grant RM, Beatty GW, Horton C, Detmer J, Eastman S. Activity of a ritonavir plus saquinavir-contain-ing regimen in patients with virologic evidence of indinavir or ritonavir failure. AIDS. 1998;12:F97–F102.
   PubMed Web of Science ®Google Scholar
• Moyle GJ, Gazzard BG, Cooper DA, Gatell J. Antiretroviral therapy for HIV infection. A knowledge-based approach to drug selection and use. Drugs. 1998;55:383–404.
   PubMed Web of Science ®Google Scholar
• Roberts NA, Craig JC, Sheldon J. Resistance and cross-resistance with saquinavir and other HIV protease inhibi-tors: Theory and practice. AIDS. 1998;12:453–460.
   PubMed Web of Science ®Google Scholar
• Lorenzi P, Opravil M, Hirschel B, et al. Impact of drug resistance mutations on virologic response to salvage therapy. AIDS. 1998;13:F17–F21.
   Web of Science ®Google Scholar
• Faktenheuer G, Theisen A, Rockstroh J, et al. Virological treatment failure of protease inhibitor therapy in an unselected cohort of HIV-infected patients. AIDS. 1997;11:F113–F116.
   PubMed Web of Science ®Google Scholar
• D'Arminio Monforte A, Testori V, Adorni F, et al. CD4 cell counts at the third month of HAART may predict clinical failure. AIDS. 1999;13:1669–1676.
   PubMed Web of Science ®Google Scholar
• Battegay M, Harr T, Sponagel L. Salvage treatment against human immunodeficiency virus. Ann Med. 1999;31:253–260.
   PubMed Web of Science ®Google Scholar
• Fäktenheuer G, Hoetelmans RMW, Hunn N, et al. Salvage therapy with regimens containing ritonavir and saquinavir in extensively pretreated HIV-infected patients. AIDS. 1999;13:1485–1489.
   PubMed Web of Science ®Google Scholar
• Ledergerber B, Egger M, Opravil M, et al. Clinical progres-sion and virological failure on highly active antiretroviral therapy in HIV-1 patients: A prospective cohort study. Lancet. 1999;353:863–868.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hecht FM, Swanson M, et al. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: Response to both initial and salvage therapy. AIDS. 1999;13:F35–F43.
   PubMed Web of Science ®Google Scholar
• Wit FWNM, Van Leeuwen R, Weverling GJ, et al. Outcome and predictors of failure of highly active antiretroviral therapy: One-year follow-up of a cohort of human immuno-deficiency virus type 1-infected persons. J Infect Dis. 1999;179:790–798.
   PubMed Web of Science ®Google Scholar
• Seminari E, Maggiolo F, Villani P, et al. Efavirenz, nelfinavir, and stavudine rescue combination therapy in HIV-1-posi-tive patients heavily pretreated with nucleoside analogues and protease inhibitors. J Acquir Immune Defic Syndr. 1999;22:453–460.
   PubMed Web of Science ®Google Scholar
• Grabar S, Pradier C, Le Corfec E, et al. Factors associated with clinical and virological failure in patients receiving a triple therapy including a protease inhibitor. AIDS. 2000; 14:141–149.
   PubMed Web of Science ®Google Scholar
• Shulman NS, Zolopa AR, Passaro DJ, et al. Efavirenz and adefovir dipivoxil-based salvage therapy in highly treat-ment-experienced patients: Clinical and genotypic predic-tors of virologic response. J Acquir Immune Defic Syndr. 2000;23:221–226.
   PubMed Web of Science ®Google Scholar
• Casado JL, Hertogs K, Ruiz L, et al. Non-nucleoside re-verse transcriptase inhibitor resistance among patients failing a nevirapine plus protease inhibitor-containing regi-men. AIDS. 2000;14:F1–F7.
   PubMed Web of Science ®Google Scholar
• Khanna N, Klimkait T, Schiffer V, et al. Salvage therapy with abacavir plus a non-nucleoside reverse transcriptase in-hibitor and a protease inhibitor in heavily pre-treated HIV-1 infected patients. AIDS. 2000;14:791–799.
   PubMed Web of Science ®Google Scholar
• Paolucci S, Baldanti F, Maserati R, et al. Quantification of the impact of HIV-1 reverse transcriptase and protease mutations on the efficacy of rescue HAART. Antiviral Res. 2000; 45:101–114.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Hellmann, NS, Grant RM, et al. Novel four-drug salvage treatment regimens after failure of a human immu-nodeficiency virus type 1 protease inhibitor-containing regimen: Antiviral activity and correlation of baseline phe-notypic drug susceptibility with virologic outcome. J Infect Dis. 1999;179:1375–1381.
   PubMed Web of Science ®Google Scholar
• Maggiolo F, Maserati R, Pan A, CasteIli F, Suter F. Salvage therapy in HIV-positive patients with a previous therapeutic experience with protease inhibitors. AIDS. 1999;13:1591–1592.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Chiodo F. Four-drug salvage antiretroviral treatment including nelfinavir and efavirenz in highly treated children with congenital HIV disease. Int J STD AIDS. 2000; 11:132–133.
   PubMed Web of Science ®Google Scholar
• Regazzi MB, Villani P, Maserati R, et al. Clinical pharmaco-kinetics of nelfinavir combined with efavirenz and stavudine during rescue treatment of heavily pretreated HIV-infected patients. J Antimicrob Chemother. 2000;45:343–347.
   PubMed Web of Science ®Google Scholar
• Harris M, Montaner JS. Clinical uses of non-nucleoside reverse transcriptase inhibitors. Rev Med Virol. 2000;10:217–229.
   PubMed Web of Science ®Google Scholar
• Piketty C, Race E, Castiel P, et al. Efficacy of a five-drug combination including ritonavir, saquinavir and efavirenz in patients who failed on a conventional triple-drug regimen: Phenotypic resistance to protease inhibitors predicts out-come of therapy. AIDS. 1999;13:F71–F77.
   PubMed Web of Science ®Google Scholar
• Palmer S, Shafer RW, Merigan TC. Highly drug-resistant HIV-1 clinical isolates are cross-resistant to many antiretroviral compounds in current clinical development. AIDS. 1999; 13:661–667.
   PubMed Web of Science ®Google Scholar
• Bernasconi E, Magenta L, Piffaretti JC, Carota A, Moccetti T. Are nelfinavir-containing regimens effective as second-line triple therapy? AIDS. 2000;14:59–68.
   Google Scholar
• Moyle GJ, Wilkins E, Leens C, Cheesbrough A, Reynolds B, Gazzard BG. Salvage therapy with abacavir plus efavirenz or nevirapine in HIV-1-infected persons with pre-vious nucleoside analogue and protease inhibitor use. AIDS. 2000;14:1453–1454.
   PubMed Web of Science ®Google Scholar
• Manfredi R, Chiodo F. First-line nevirapine in combination with nucleoside analogues compared with nevirapine added to a salvage HAART. Infection. 2000;28:167–170.
   PubMed Web of Science ®Google Scholar
• Gray CM, Schapiro JM, Winters MA, Merigan TC. Changes in CD4+ and CD8+ T cells subsets in response to highly active antiretroviral therapy in HIV type 1-infected patients with prior protease inhibitor experience. AIDS Res Hum Retroviruses. 1998;14:561–569.
   PubMed Web of Science ®Google Scholar
• Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunological response without decrease in virus load in patients with AIDS after 24 months of highly active antiretroviral therapy. Clin Infect Dis. 1999;29:1423–1430.
   PubMed Web of Science ®Google Scholar
• Deeks SG, Barbour JD, Martin JN, Swanson MS, Grant RM. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with hu-man immunodeficiency virus infection. J Infect Dis. 2000;181:946–953.
   PubMed Web of Science ®Google Scholar